The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

npj Vaccines 2026 Open access

Read full text
Authors: Ian Escudero, Dieter Gniel, Shibadas Biswal, Eckhardt Petri, Gonzalo Perez, Mayuri Sharma, John Weil, Derek Wallace
DOI: 10.1038/s41541-025-01366-9
Cited by: 3
References: 70

Abstract

The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development. These include decisions around vaccine composition, assessment of factors that may be associated with the safety of live-attenuated viral vaccines, dosing schedule, immunogenicity assessments, and design of the pivotal phase 3 efficacy study.

Fields of Study & Subjects

Mosquito-borne diseases and control Viral Infections and Outbreaks Research Virology and Viral Diseases

Publication details

Journal / source
npj Vaccines
Publisher
Springer Science and Business Media LLC
Volume
11
Issue
1
Pages
46–46
Publication date
2 February 2026
Language
EN